Tolterodine for the treatment of overactive bladder: a review

Bibliography

• ABRAMS P, CARDOZO L, FALL M et al.:The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology (2003) 61:37–49.
   PubMed Web of Science ®Google Scholar
• •This is a recent update on the terminology utilised in the field of voiding dysfunction.
   Google Scholar
• STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol (2003) 20:327–336.
   PubMed Web of Science ®Google Scholar
• HU TW, WAGNER TH, BENTKOVER JD et al: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61:1123–1128.
   PubMed Web of Science ®Google Scholar
• HEALTH NIO: Disease-specific estimates of direct and indirect costs of illness and NIH support: fiscal year 2000 update. (2004).
   Google Scholar
• GARNETT S, ABRAMS P: The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J. Urol. (2003) 169:843–848.
   Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int (2001) 87:760–766.
   PubMed Web of Science ®Google Scholar
• HEIDRICH SM, WELLS TJ: Effects of urinary incontinence: psychological well being and distress in older community-dwelling women. J. Gerontol Nurs. (2004) 30:47–54.
   PubMedGoogle Scholar
• BROWN JS, VITTINGHOFF E, WYMAN JF et al: Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J. Am. Geriatr. Soc. (2000) 48:721–725.
   PubMed Web of Science ®Google Scholar
• HU KK, BOYKO EJ, SCHOLES D et al: Risk factors for urinary tract infections in postmenopausal women. Arch. Intern. Med. (2004) 164:989–993.
   PubMed Web of Science ®Google Scholar
• BROWN JS, MCGHAN WF, CHOKROVERTY S: Comorbidities associated with overactive bladder. Am. J. Manag Care (2000) 6(11 Suppl.):5574–5579.
   Google Scholar
• WEIN AJ, ROVNER ES: The overactive bladder: an overview for primary care health providers. Int. J. Fend Womens Med. (1999) 44:56–66.
   PubMed Web of Science ®Google Scholar
• ANDERSSON KE, YOSHIDA M: Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur. Urol (2003) 43:1–5.
   Web of Science ®Google Scholar
• CHAPPLE CR: Muscarinic receptor antagonists in the treatment of overactive bladder. Urology (2000) 55:33-46; discussion 50.
   Google Scholar
• ••This is an excellent review of availabledrugs for treating OAB by one of the leading investigators in the world.
   Google Scholar
• CHAPPLE CR, YAIVIANISHI T, CHESS-WILLIAMS R: Muscarinic receptor subtypes and management of the overactive bladder. Urology (2002) 60:82-88; discussion 8–9.
   Google Scholar
• CAULFIELD MP: Muscarinic receptors-characterization, coupling and function. Pharmacol Ther. (1993) 58:319–379.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, MATSUI M, UCHIDA K et al: M(3) muscarinic acetylcholine receptor plays a critical role in parasympathetic control of salivation. Physiol (2004) 558:561–575.
   Web of Science ®Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. (1997) 327:195–207.
   PubMed Web of Science ®Google Scholar
• STAHL MM, EKSTROM B, SPARF B, MATTIASSON A. ANDERSSON KE: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for
   Google Scholar
• •• the treatment of detrusor overactivity. Neurourol Urodyn. (1995) 14:647–655.
   Google Scholar
• VAN KERREBROECK P, KREDER K, JONAS U, ZINNER N, WEIN A: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 57:414–421.
   PubMed Web of Science ®Google Scholar
• •The pivotal study demonstrating the improved efficacy and tolerability of the ER versus IR formulation of tolterodine.
   Google Scholar
• ROVNER ES, WEIN AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur. Urol (2002) 41:6–14.
   PubMed Web of Science ®Google Scholar
• ABRAMS P: Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin. Pharmacother. (2001) 2:1685–1701.
   PubMedGoogle Scholar
• OLSSON B, SZAMOSI J: Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet. (2001) 40:227–235.
   PubMed Web of Science ®Google Scholar
• HILLS CJ, WINTER SA, BALFOUR JA: Tolterodine. Drugs (1998) 55:813-20; discussion 21–22.
   Google Scholar
• CLEMETT D, JARVIS B: Tolterodine: areview of its use in the treatment of overactive bladder. Drugs Aging (2001) 18:277–304.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L, GILLBERG PG, SPARF B: Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol (1997) 81:169–172.
   PubMedGoogle Scholar
• NILVEBRANT L: Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol. Toxicol (2002) 90:260–267.
   PubMedGoogle Scholar
• CHAPPLE C: Tolterodine once daily: selectivity for the bladder over effects on salivation compared to Ditropan XL. J. Urol (2001) 165:253.
   PubMedGoogle Scholar
• CHAPPLE CR, NILVEBRANT L: Tolterodine: selectivity for the urinary bladder over the eye (as measured by visual accommodation) in healthy volunteers. Drugs RD (2002) 3:75–81.
   PubMedGoogle Scholar
• OLSSON B, SZAMOSI J: Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin. Pharmacokinet. (2001) 40:135–143.
   PubMed Web of Science ®Google Scholar
• SATHYAN G, DMOCHOWSKI RR, APPELL RA, GUO C, GUPTA SK: Effect of antacid on the pharmacokinetics of extended-release form of tolterodine and oxybutynin. Clin. Pharmacokinet. (2004) 43:1059–1068.
   PubMed Web of Science ®Google Scholar
• ROMANZI L: Tolterodine extended-release action not affected by stomach pH. IUGA/CFA. Melbourne, Australia (2001).
   Google Scholar
• BRYNNE N, STAHL MM, HALLEN B et al: Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int. J. Clin. Pharmacol Ther. (1997) 35:287–295.
   PubMed Web of Science ®Google Scholar
• PAHLMAN I, GOZZI P: Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm. Drug Dispos. (1999) 20:91–99.
   PubMed Web of Science ®Google Scholar
• POSTLIND H, DANIELSONA, LINDGREN A, ANDERSSON SH: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab. Dispos. (1998) 26:289–293.
   PubMed Web of Science ®Google Scholar
• ALVAN G, BECHTEL P, ISELIUS L, GUNDERT-REMY U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol (1990) 39:533–537.
   PubMed Web of Science ®Google Scholar
• BRYNNE N, DALEN P, ALVAN G, BERTILSSON L, GABRIELSSON J: Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin. Pharmacol Ther. (1998) 63:529–539.
   PubMed Web of Science ®Google Scholar
• BRYNNE N, SVANSTROM C, ABERG-WISTEDT A, HALLEN B, BERTILSSON L: Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br. J. Clin. Pharmacol (1999) 48:553–563.
   PubMed Web of Science ®Google Scholar
• HUA TC, PAN A. CHAN C et ell.: Effectof duloxetine on tolterodine pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol (2004) 57:652–656.
   Web of Science ®Google Scholar
• BRYNNE N, FORSLUND C, HALLEN B, GUSTAFSSON LL, BERTILSSON L: Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br. J. Clin. Pharmacol. (1999) 48:564–572.
   PubMed Web of Science ®Google Scholar
• RAHIMY M, HALLEN B, NARANG P: Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelfirschung (2002) 52:890–895.
   PubMed Web of Science ®Google Scholar
• OLSSON B, LANDGREN BM: The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Clin. Ther. (2001) 23:1876–1888.
   PubMed Web of Science ®Google Scholar
• EDWARDS KR, O'CONNOR JT: Risk ofdelirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J. Am. Geriatr. Soc. (2002) 50:1165–1166.
   PubMed Web of Science ®Google Scholar
• DONNELLAN CA, FOOK L, MCDONALD P, PLAYFER JR: Oxybutynin and cognitive dysfunction. Br. Med. J. (1997) 315:1363–1364.
   PubMed Web of Science ®Google Scholar
• •Antimuscarinic compounds may have CNS effects, as noted in this study.
   Google Scholar
• LEVIEN TL, BAKER DR: Cytochrome P450 drug interactions. Pharmacist's Letter (2004) Detail document no. 150400.
   Google Scholar
• KREDER KJ, BRUBAKER L, MAINPRIZE T: Tolterodine is equally effective in patients with mixed incontinence and those with urge incontinence alone. BJU Int. (2003) 92:418–421.
   PubMed Web of Science ®Google Scholar
• •Patients with urge-predominant mixed incontinence may respond to drug therapy directed at the urge component, as seen in this study.
   Google Scholar
• KHULLAR V, HILLS, LAVAL K-U, SCHIOTZ HA, JONAS U, VERSI E: Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: A randomized, placebo-controlled trial. Urology (2004) 64:269–275.
   PubMed Web of Science ®Google Scholar
• DIOKNO AC, APPELL RA, SAND PK et al: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. (2003) 78:687–695.
   PubMed Web of Science ®Google Scholar
• ••In a severely symptomatic patientpopulation, both tolterodine and oxybutynin demonstrated satisfactory efficacy in treating the symptoms of OAB.
   Google Scholar
• HOMMA Y, PAICK JS, LEE JG, KAWABE K: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo- controlled trial. BJU Int. (2003) 92:741–747.
   PubMed Web of Science ®Google Scholar
• SUSSMAN D, GARELY A: Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr. Med. Res. Opin. (2002) 18:177–184.
   PubMed Web of Science ®Google Scholar
• COYNE K, MATZA L: Patient perceptionof bladder condition is a valid tool for evaluating the efficacy of overactive bladder therapy. Int. Urogynecol J. Pelvic Floor Dysfiinct. (2002) 13:S83.
   Google Scholar
• DMOCHOWSKI RR, SAND PK, ZINNER NR, GITTELMAN MC, DAVILA GW, SANDERS SW: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 62:237–242.
   PubMed Web of Science ®Google Scholar
• •The oxybutynin patch compared favourably to tolterodine in treating the symptoms of OAB. Both agents were well tolerated, although the incidence of patch site reactions in the oxybutynin group was notable.
   Google Scholar
• APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50:90-96; discussion 7–9.
   Google Scholar
• RICCI JA, BAGGISH JS, HUNT TL et al: Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin. Ther. (2001) 23:1245–1259.
   PubMed Web of Science ®Google Scholar
• HERZOG AR, FULTZ NH, NORMOLLE DP: Methods used to managed urinary incontinence by older adults in the community. J. Am. Geriatr. Soc. (1989) 37:339–347.
   PubMed Web of Science ®Google Scholar
• SIAMI P, SEIDMAN LS, LAMA D: A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin. Ther. (2002) 24:616–628.
   PubMed Web of Science ®Google Scholar
• LANDIS JR, KAPLAN SA, SWIFT S: Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J. Urol (2004) 171:752–756.
   PubMed Web of Science ®Google Scholar
• FREEMAN R, HILLS, MILLARD R, SLACK M, SUTHERST J: Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet. GynecoL (2003) 102:605–611.
   PubMed Web of Science ®Google Scholar
• APPELL RA, ABRAMS P, DRUTZ HP, VAN KERREBROECK PE, MILLARD R, WEIN A: Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol (2001) 19:141–147.
   PubMed Web of Science ®Google Scholar
• ABRAMS P, MALONE-LEE J, JACQUETIN B et al.: Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging (2001) 18:551–560.
   PubMed Web of Science ®Google Scholar
• KREDER K, MAYNE C, JONAS U: Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol (2002) 41:588–595.
   PubMed Web of Science ®Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol (1997) 104:988–993.
   PubMedGoogle Scholar
• LAWRENCE M, GUAY DR, BENSON SR, ANDERSON MJ: Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy (2000) 20:470–475.
   PubMed Web of Science ®Google Scholar
• CALLAHAN MJ: Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J. Clin. Gastroenterol (2002) 35:S58–S67.
   Google Scholar
• CHOPPIN A, EGLEN RM: Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br. J. Pharmacol (2001) 132:835–842.
   PubMed Web of Science ®Google Scholar
• HABGOOD MD, BEGLEY DJ, ABBOTT NJ: Determinants of passive drug entry into the central nervous system. Cell. Mol NeurobioL (2000) 20:231–253.
   PubMed Web of Science ®Google Scholar
• NILVEBRANT L: Clinical experiences with tolterodine. Life Sci. (2001) 68:2549–2556.
   PubMed Web of Science ®Google Scholar
• TODOROVA A, VONDERHEID-GUTH B, DIMPFEL W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. (2001) 41:636–644.
   PubMed Web of Science ®Google Scholar
• TSAO JW, HEILMAN KM: Transient memory impairment and hallucinations associated with tolterodine use. N Engl. J. Med. (2003) 349:2274–2275.
   PubMed Web of Science ®Google Scholar
• SIEGLER EL, REIDENBERG M: Treatment of urinary incontinence with anticholinergics in patients taking cholinesterase inhibitors for dementia. Clin. Pharmacol Ther. (2004) 75:484–488.
   PubMed Web of Science ®Google Scholar
• WOMACK KB, HEILMAN KM: Tolterodine and memory: dry but forgetful. Arch. NeuroL (2003) 60:771–773.
   PubMed Web of Science ®Google Scholar
• MALONE-LEE JG, WALSH JB, MAUGOURD MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder./ Am. Geriatr. Soc. (2001) 49:700–705.
   PubMed Web of Science ®Google Scholar
• MALONE-LEE J, SHAFFU B, ANAND C, POWELL C: Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J. Urol (2001) 165:1452–1456.
   PubMed Web of Science ®Google Scholar
• •It is important to note that both tolterodine and oxybutynin are efficacious in older patients, a group which is disproportionately affected by this condition.
   Google Scholar
• MICHEL MC, SCHNEIDER T, KREGE S, GOEPEL M: Does gender or age affect the efficacy and safety of tolterodine?J. Urol (2002) 168:1027–1031.
   Web of Science ®Google Scholar
• ZINNER NR, MATTIASSON A. STANTON SL: Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. (2002) 50:799–807.
   PubMed Web of Science ®Google Scholar
• MILLARD R, TUTTLE J, MOORE K et al.: Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J. Urol (1999) 161:1551–1555.
   PubMed Web of Science ®Google Scholar
• VAN KERREBROECK P, ALE: Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. NeurouroL Urodyn. (1997) 16:478–479.
   Google Scholar
• ABRAMS P, FREEMAN R, ANDERSTROM C, MATTIASSON A: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol (1998) 81:801–810.
   PubMedGoogle Scholar
• DRUTZ HP, APPELL RA, GLEASON D, KLIMBERG I, RADOMSKI S: Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int. Urogynecol. J. Pelvic Floor Dysfiinct. (1999) 10:283–289.
   PubMedGoogle Scholar
• WALLIS RM, NAPIER CM: Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci. (1999) 64:395–401.
   PubMed Web of Science ®Google Scholar
• NEWGREEN DT, ANDERSON CWP, CARTER AJ, NAYLOR AM: Darifenacin-a novel bladder-selective agent for the treatment of urge incontinence. NeurouroL Urodyn. (1995) 14:95–96.
   Google Scholar
• SMULDERS RA, KRAUWINKEL WJ, SWART PJ, HUANG M: Pharmacolcinetics and safety of solifenacin succinate in healthy young men. J. Clin. PharmacoL (2004) 44:1023–1033.
   PubMed Web of Science ®Google Scholar
• KUIPERS M, TRAN DD, KRAUWINKEL WJ, ABILA B, MULDER H: Absolute bioavailability of YM905 in healthy male volunteers: a single-dose, randomized, two-period crossover study. NeurouroL Urodyn. (2002) 4:296–297.
   Google Scholar
• IKEDA K, KOBAYASHI S, SUZUKI M et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch. Pharm. (2002) 366:97–103.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, ARANO P, BOSCH JL, DE RIDDER D, KRAMER AE, RIDDER AM: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase II dose-finding study. BJU Int. (2004) 93:71–77.
   PubMed Web of Science ®Google Scholar
• CHAPPLE CR, RECHBERGER T, AL-SHUKRI S et al.: Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. (2004) 93:303–310.
   PubMed Web of Science ®Google Scholar
• MADERSBACHER H, STOHRER M, RICHTER R, BURGDORFER H, HACHEN HJ, MURTZ G: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br. J. UroL (1995) 75:452–456.
   PubMedGoogle Scholar